Skip to content

Author

Noushin Nabavi

We have 1 of 4 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Oncogenic KRAS in Cancer Immunotherapy: From Oncogenic Signaling to Tumor-Immune Ecosystem Regulation

Current evidence supports a paradigm in which KRAS functions not only as an oncogenic driver but also as a regulator of tumor-immune interactions, shaping therapeutic responsiveness and providing opportunities for biomarker-guided and combination-based immunotherapy in KRAS-mutant cancers.

M. Ashrafizadeh, Noushin Nabavi, Yifei Xu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.